Former CDC Head and Merck’s Current Vaccine Division President Julie Gerberding Sells $9.1 Million in Merck Pharmaceutical Shares as Gardasil Vaccine Gets Bad Press
SEC filings reveal that Merck’s Vaccine Division President Julie Gerberding sold over half her Merck shares in January for $9.1 Million. That transaction followed a spate of bad news for Merck’s flagship Gardasil vaccine. Last month, Cancer Research UK announced an alarming 54% rise in cervical cancer among 24-29-year-olds, the first generation to receive the HPV jabs. The following day, the Journal of the Royal Society of Medicine published a withering critique of Gardasil’s crooked clinical trials, “It is still uncertain whether human papillomavirus (HPV) vaccination prevents cervical cancer as trials were not designed to detect this outcome.” As Gerberding knows, those trials revealed that Gardasil dramatically RAISES (by+44.6%) the risk of cervical cancer among women with a current infection or those previously exposed to HPV. Merck is now fighting existential fraud lawsuits on both the MMR and Gardasil vaccines, that threaten licensing for those key products. Fat rats are always the first to jump ship.